KAKKIS EMIL D (President & CEO) sold 5.0% of their position (30K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $1.44M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/2/2024ACC: 0001209191-24-000071
DirectorOfficer· President & CEO
Since Mar 2026
-30K
Net shares
Net seller
$1.44M
Total sold
1
Open market trades
0B · 1S
1
Total transactions
30K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−30K
Price / share
$47.87
Trade value
$1.44M
% of position
5.0%
12/29/2023
599.77K→569.77K
Total
Net shares
−30K
Net value
-$1.44M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/29/2023 | S · Sale | −30K | $47.87 | $1.44M | 5.0% | 599.77K | 569.77K |
| Total | −30K | -$1.44M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned2.26M
Total
2.26M indirect2.26M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 2.26M | Indirect |
| Total | 2.26M | 2.26M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported